26, May 2025
Anupam Rasayan India Limited Reports Q4 & FY25 Results
Surat/ Mumbai, May 26, 2025: Anupam Rasayan India Ltd., one of India’s leading custom synthesis and specialty chemical player, has announced its financial results for the quarter ended March 31, 2025.
Consolidated Financial Highlights for year ended March 31, 2025:
- Total revenue for FY25 was at ₹14,485 million as compared to ₹15,053 million in FY24; down 4% YoY.
- EBITDA (incl. other income) was at ₹4,123 million in FY25 as compared to ₹4,109 million in FY24, this would translate into 28% EBITDA margin in FY25.
- Profit After Tax was at ₹1,600 million in FY25 as compared to ₹1,674 million in FY24.
Consolidated Financial Highlights for Quarter ended March 31, 2025:
- Total revenue for Q4FY25 was at ₹5,057 million as compared to ₹4,130 million in Q4FY24; up 22% YoY.
- EBITDA (incl. other income) was at ₹1,500 million in Q4FY25 as compared to ₹1,047 million in Q4FY24, up 43% and this would translate into 30% EBITDA margin in this quarter.
- Profit After Tax was at ₹629 million in Q4FY25 as compared to ₹405 million in Q4FY24; up 56% YoY.
Speaking on the performance, Mr Anand Desai, Managing Director, Anupam Rasayan commented, “Consolidated revenue for the quarter Q4FY25 stood at INR 506 crores registering a growth of 22% YoY and 31% QoQ. Consolidated revenue for the full year FY25 stood at INR 1,448 crores registering a degrowth of 4% YoY. This performance was supported by growth in pharma and polymer coupled with strong performance from Tanfac. Margins have remained consistent this quarter, reflecting our focus on operational efficiency and a favourable product mix.
While H1 FY25 was subdued due to weak macro conditions, I am pleased to share that H2 has shown clear signs of recovery — particularly in Q4 FY25 where we have seen meaningful improvement with sales increasing both year- on-year and sequentially. We remain confident in our ability to return to the historical growth rates achieved prior to the recent slowdown.”
- 0
- By Neel Achary
